ViroCell Partners with UCL to Advance Childhood Cancer Research; Bristol Myers Squibb Announces Promising Results in Lymphoma and Myeloma Studies

The partnership leverages ViroCell's expertise in lentiviral vector manufacturing for innovative CAR T-cell therapy. Meanwhile, Bristol Myers Squibb's studies demonstrate potential of CELMoD™ agent golcadomide in non-Hodgkin lymphomas and progress in multiple myeloma research.